Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 9/20 | 0.86 |
| ▸ | RRM1 | P23921 | 2/20 | 0.58 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.55 |
| ▸ | ATP4A | P20648 | 2/20 | 0.54 |
| ▸ | ATP4B | P51164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304878 | 0.93 | PLTP (1.00) | PLTPRRM1RRM2BTOP1LMNA | |
| SCHEMBL10002071 | 0.85 | PLTP (0.63) | PLTPRRM1RRM2BTOP1MAPT | |
| Coh-29 SCHEMBL29424344 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1KDM4E | |
| Coh-29 SCHEMBL10036527 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1KDM4E | |
| Coh-29 SCHEMBL31436912 | 0.81 | PLTP (0.61) | PLTPRRM1RRM2BTOP1KDM4E | |
| SCHEMBL1304137 | 0.81 | PLTP (0.80) | PLTPTOP1LMNAKDM4EALDH1A1 | |
| SCHEMBL12940263 | 0.81 | PLTP (0.59) | PLTPRRM1RRM2BTOP1ALDH1A1 | |
| SCHEMBL3601552 | 0.79 | ATP4A (0.61) | PLTPATP4AATP4BLMNAKDM4E | |
| SCHEMBL17107156 | 0.74 | ALDH1A1 (0.79) | LMNAKDM4EALDH1A1POLBRAB9A | |
| SCHEMBL1303838 | 0.74 | SMN1; SMN2 (0.71) | PLTPLMNAKDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-9796692-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2017-05-18 | — | — | US | disclosed |
| US-9598385-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2016-05-05 | — | — | US | disclosed |
| US-9126960-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2015-03-26 | — | — | US | disclosed |
| US-RE45020-E1 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2014-07-15 | — | — | US | disclosed |
| US-8372983-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2012-10-04 | — | — | US | disclosed |
| US-8163783-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2011-10-06 | — | — | US | disclosed |
| US-7956076-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4112/4885RRM1 3/4885RRM2B 2/4885 |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4024/4885RRM1 3/4885RRM2B 2/4885 |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | PLTP 4112/4885RRM1 3/4885RRM2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.